Check 35,000+ stocks against 26 valuation models and 37 quality factors

Grand Brilliance Group Holdings Ltd (8372) fair value: what the stock is really worth

As of Sep 30, 2026: fair value of Grand Brilliance Group Holdings Ltd HK$0.17, price HK$0.16, upside +4.3%, quality 60 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value above price? Yes
Good quality? Yes
Add to watchlist

Healthcare · HK · ISIN KYG4136R1020

GB Thin data Sep 27, 2026

Grand Brilliance Group Holdings Ltd

8372 · HK

NeutralThe stock looks roughly fairly valued with average quality.

·Fair value HK$0.1700 · Fairly valued (+4.3%)

✓Quality 60/100

!Expensive Growth (revenue 5y +7.5 %/yr)

!Thin margins · 8.4% net margin (TTM)

✓generates free cash flow

!1.8% dividend yield · Watch coverage

!Mixed vs. peers (6/13)

!Narrow moat 35/100

!Evidence only low, so the estimate is less certain

!Weak on past: 28 out of 100

26 models, one by oneBear HK$0.1200 to bull HK$0.2400 Growth analysisrevenue history, year by year Quality 60/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch Grand Brilliance Group Holdings Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.

How to read this chart

60‑month range HK$0.0527 – HK$0.1630 · fair‑value band HK$0.1200 – HK$0.2400 · the HK$0.1630 price screens below the HK$0.1700 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 27, 2026.

Follow Grand Brilliance Group Holdings in your weekly email

Every Wednesday you see whether Grand Brilliance Group Holdings is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Grand Brilliance Group Holdings Limited, an investment holding company, engages in supplying of medical devices in Hong Kong. The company offers medical consumables; medical instruments; and medical equipment, as well as develops healthcare products. It also provides medical device solutions, such as market trend analysis, sourcing of medical devices, after-sale services, technical support and training services, medical devices leasing services, and quality assurance services; and autonomous mobile robots solutions, as well as holds trademarks. The company sells its products to government department, hospitals, elderly home, universities, non-private organization, and individual end users. Grand Brilliance Group Holdings Limited was founded in 1997 and is based in Tsuen Wan, Hong Kong.

Stock analysis

Grand Brilliance Group Holdings Ltd (8372) currently trades at HK$0.1630, while our model-based Fair Value estimate is HK$0.1700, so the stock looks roughly fairly valued today (gap 4.1%).

Valuation

Bull case: the Growth Earnings group reads highest at a median of HK$0.2100 per share, and 13 of the 26 models we run sit above the HK$0.1630 price.

Bear case: the Dividend Discount group reads lowest at HK$0.0400, and 13 of the 26 models stay below the price. Evidence for this calculation is low.

Scenario range: HK$0.1200 (bear) to HK$0.2400 (bull), the price of HK$0.1630 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 60/100 (solid quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Grand Brilliance Group Holdings Ltd reported revenue of HK$101M in FY2026 versus HK$72.0M in FY2022, a compound +8.8%/yr. Reported net income was HK$8.4M in FY2026, compounding +20.1%/yr from FY2022.

Key figures

Market cap HK$130M (≈ $16.6M) · P/E ratio 14.0 · P/S ratio 1.17 · EPS (TTM) HK$0.0200 · Dividend yield 1.8% · Net margin 8.4% · Return on equity 7.1% · Return on assets (EBIT) 5.6%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 34 out of 100 (low confidence).

What moves the price

The share trades at its 52-week high and 70% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 37% fair-value upside, at 4%, 8372 screens richer than that median.

Fair Value models

Bear HK$0.1200 Fair Value HK$0.1700 Bull HK$0.2400

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then (HK$0.0086 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Highest evidence

FCF DCF HK$0.0900 HK$0.1000 HK$0.1100 80

Growth DCF HK$0.0900 HK$0.0900 HK$0.1100 77

Residual Income HK$0.1200 HK$0.1200 HK$0.1400 76

All 26 models by family

DCF Models

FCF DCF HK$0.0900 HK$0.1000 HK$0.1100 80

Owner Earnings HK$0.2300 HK$0.3300 HK$0.4700 74

5Y Revenue Exit HK$0.1200 HK$0.1600 HK$0.2200 71

5Y EBITDA Exit HK$0.1500 HK$0.2200 HK$0.3100 72

5Y P/E Exit HK$0.1700 HK$0.2600 HK$0.3600 68

10Y Revenue Exit HK$0.1000 HK$0.1400 HK$0.1900 65

10Y EBITDA Exit HK$0.1300 HK$0.1800 HK$0.2600 66

10Y P/E Exit HK$0.1400 HK$0.2100 HK$0.3000 61

Earnings-Based

Graham-Dodd HK$0.0700 HK$0.2400 HK$0.3200 64

Lynch FV HK$0.0500 HK$0.0800 HK$0.1000 61

PEG = 1.0 HK$0.0500 HK$0.0800 HK$0.1000 57

EPV HK$0.1300 HK$0.1400 HK$0.1500 70

Dividend Discount

Gordon GGM HK$0.0200 HK$0.0400 HK$0.0700 65

DDM Multi-Stage HK$0.0200 HK$0.0400 HK$0.0500 66

Multiples

P/E Multiple HK$0.1700 HK$0.2300 HK$0.2900 63

P/S Multiple HK$0.1300 HK$0.1800 HK$0.2200 58

P/B Multiple HK$0.1300 HK$0.1800 HK$0.2200 55

EV/EBIT HK$0.1700 HK$0.2100 HK$0.2500 63

EV/EBITDA HK$0.2000 HK$0.2500 HK$0.2900 64

EV/Revenue HK$0.1400 HK$0.1800 HK$0.2100 52

Asset-Based

NCAV (Graham) HK$0.0700 HK$0.1000 HK$0.1500 51

Growth DCF

Growth DCF HK$0.0900 HK$0.0900 HK$0.1100 77

Rev-Margin DCF HK$0.1200 HK$0.1600 HK$0.2100 71

Economic Profit

Residual Income HK$0.1200 HK$0.1200 HK$0.1400 76

ROIC Compounder HK$0.1300 HK$0.1400 HK$0.1600 70

Growth Earnings

Growth-Adj P/E HK$0.1500 HK$0.2100 HK$0.2700 68

Open the full fair value analysis →

Notify me when 8372 reaches fair value

Put 8372 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 60/100

Of which business quality 61 · Market factors (momentum, volatility) 74

Profitability 47

Margins and returns on capital today

Quality Growth 29

Are margins and returns improving?

Cashflow 31

Earnings quality: real cash, not paper profit

Fin. Strength 100

Balance sheet, leverage, solvency risk

Investment 81

Disciplined investing over empire-building

Low Volatility 62

Calm price path (market factor)

Momentum 71

Price trend over the last 3–12 months (market factor)

52W Momentum 94

Distance to the 52-week high (market factor)

Net Issuance 82

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 55/100

The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Revenue growth 1 year

+6.6%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+9.5%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+7.5%

Start year 2021 (pandemic). Over 10 years: +6.7% a year

Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+6.7%

’16

’17

’18

’19

’20

’21

’22

’23

’24

’25

’26

What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.

+3.2%

Earnings growth per share plus dividend.

Earnings per share, growth per year+1.4%

Dividend (yield on the price)1.8%

Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.1.4% vs −3.8%, picking up

Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.10% → 7%

Start year 2021 (pandemic)

Growth Forecast

A lot of optimism in the price

The price assumes more growth than the company has delivered so far.

What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).

+34.0%

Yearly growth needed for the next five years to justify today's price.

What forecasts expect

n/a

No analyst forecast available.

After inflation (Hong Kong: IMF forecast 2.1% a year to 2030, 1.8% from 2016 to 2025) that is about +31.2% a year for the price.

Watch 8372, get fair value alerts →

Compare Grand Brilliance Group Holdings Ltd with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Distribution · 78 stocks

Beats the industry median on 6/13 measures

A mixed picture versus its industry peers.

Valuation

Quality Score 60 · Top 25%

Fair Value upside +4.3% · Below median

Profitability

Return on equity (TTM) 7.1% · Above median

Return on assets 3.2% · Above median

Net margin (TTM) 8.4% · Top 25%

Operating margin (TTM) 7.8% · Top 25%

Growth and dividend

Revenue growth −8.6% · Bottom 25%

Dividend yield (TTM) 1.8% · Below median

Valuation Multiplesvs Medical Distribution median · lower = cheaper

P/E (TTM) 14.0× · Cheaper than median

P/B 1.11× · Pricier than median

P/S (TTM) 1.30× · Priciest 25%

P/FCF 111.3× · Priciest 25%

EV/EBITDA 10.3× · Pricier than median

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)39 · sector 41

FUTURE (revenue growth)0 · sector 12

PAST (return on equity)28 · sector 27

HEALTH (low debt)0 · sector 97

DIVIDEND (yield)37 · sector 58

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Distribution stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value
McKesson Corporation MCK	$864.82	$822.74	−5%
Cencora, Inc COR	$306.92	$215.20	−30%
Cardinal Health, Inc CAH	$220.29	$162.84	−26%
Henry Schein, Inc HSIC	$86.37	$76.77	−11%
Shanghai Pharmaceuticals Holding 601607	¥16.02	¥42.67	+166%
Sinopharm Group 1099	HK$14.88	HK$55.77	+275%
Galenica AG GALE	CHF 82.55	CHF 61.79	−25%
Guangzhou Baiyunshan Pharmaceutical Holdings 600332	¥19.39	¥26.64	+37%
Jointown Pharmaceutical Group 600998	¥5.05	¥9.84	+95%
China National Medicines Corporation 600511	¥25.80	¥58.47	+127%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Grand Brilliance Group Holdings Ltd · Fair Value
HK$0.1700 +4%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/8372" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">Grand Brilliance Group Holdings Ltd · Fair Value</span><br><b style="font-size:20px">HK$0.1700</b> <span style="color:var(--fvc-g-mitte);font-weight:700;font-size:14px">+4%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "Grand Brilliance Group Holdings Ltd Fair Value". https://www.fairvalue-calculator.com/stock/8372

Frequently asked questions

Is Grand Brilliance Group Holdings Ltd (8372) overvalued or undervalued?

As of Sep 27, 2026, our model estimates a fair value of HK$0.1700 versus a price of HK$0.1630, about +4% upside (fairly valued).

What is the fair value of 8372?

Our model-based fair value for Grand Brilliance Group Holdings Ltd is HK$0.1700 (as of Sep 27, 2026), built from audited fundamentals. The current price: HK$0.1630.

What is the quality score of 8372?

Grand Brilliance Group Holdings Ltd has a Quality Score of 60/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Grand Brilliance Group Holdings Ltd (8372)?

Our model-based price target is the fair value of HK$0.1700 (as of Sep 27, 2026) from 26 valuation models. Cautious scenario HK$0.1200, optimistic scenario HK$0.2400. It is a calculation from audited fundamentals, not an analyst target.

What is the Grand Brilliance Group Holdings Ltd stock forecast for 2026?

Our models put fair value at HK$0.1700, about +4% upside versus a price of HK$0.1630 (fairly valued). Cautious scenario HK$0.1200, optimistic scenario HK$0.2400. The calculation is refreshed regularly with new filings.

What is the revenue of Grand Brilliance Group Holdings Ltd (8372)?

Grand Brilliance Group Holdings Ltd reported trailing-twelve-month revenue of about HK$101M (latest available figure, as of Sep 27, 2026).

Does Grand Brilliance Group Holdings Ltd pay a dividend?

Grand Brilliance Group Holdings Ltd currently shows a dividend yield of about 1.84% relative to its recent price (as of Sep 27, 2026).

What growth is priced into Grand Brilliance Group Holdings Ltd (8372)?

For today's price to be fair in a discounted-cash-flow model, Grand Brilliance Group Holdings Ltd would have to grow free cash flow by +34.0 % per year for five years (discount rate 10.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +7.5 % per year. As of Sep 27, 2026.

What discount rate (WACC) does the fair value of 8372 use?

Our models discount Grand Brilliance Group Holdings Ltd at 10.3 %: a base by market capitalisation (nano), country premium for Hong Kong. The same rate applies in all 26 models.

What is a reverse DCF?

A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Grand Brilliance Group Holdings Ltd that is +34.0 % per year a year over ten years, using the same discount rate (10.3 %) and the same formula as our fair value.

How much growth has Grand Brilliance Group Holdings Ltd (8372) delivered so far?

Over the past 5 years revenue at Grand Brilliance Group Holdings Ltd grew +7.5 % a year. The price currently implies +34.0 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.

How fast is the sector of Grand Brilliance Group Holdings Ltd (8372) growing?

The median revenue growth in the sector is +4.3 % a year. That is the yardstick for the growth priced into Grand Brilliance Group Holdings Ltd (+34.0 % per year a year): it shows whether the expectation is within the usual range or beyond it.

What is the free cash flow yield of Grand Brilliance Group Holdings Ltd (8372)?

The free-cash-flow yield on the price is 0.90 %: that much free cash flow Grand Brilliance Group Holdings Ltd produces per unit of market value. When it exceeds the discount rate of our models (10.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.

What is the intrinsic value of Grand Brilliance Group Holdings Ltd (8372)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Grand Brilliance Group Holdings Ltd it is HK$0.1700 per share (as of Sep 27, 2026), against a price of HK$0.1630. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).

Is Grand Brilliance Group Holdings Ltd stock overvalued or undervalued in 2026?

As of Sep 27, 2026, 8372 trades below its calculated fair value: price HK$0.1630, fair value HK$0.1700, a gap of about +4% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of 8372?

No. The price is what the market pays today (HK$0.1630); the fair value is what the company's own numbers justify (HK$0.1700). For Grand Brilliance Group Holdings Ltd the two are HK$0.0070 per share apart. That gap is exactly why we show both numbers side by side.

How much is Grand Brilliance Group Holdings Ltd worth?

The market values Grand Brilliance Group Holdings Ltd at about HK$130M (market capitalisation, as of Sep 27, 2026). Per share that is HK$0.1630; our models calculate a fair value of HK$0.1700 per share.

What do the bullish and bearish scenarios say about 8372?

Our models span a range for Grand Brilliance Group Holdings Ltd: cautious scenario HK$0.1200, base HK$0.1700, optimistic HK$0.2400 per share (as of Sep 27, 2026, price HK$0.1630). The range comes from different growth and margin assumptions, not from analyst opinions.

What is the P/E ratio of 8372?

Grand Brilliance Group Holdings Ltd trades at a price-to-earnings ratio of 14.0 (as of Sep 27, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$0.1700 is built from several models across several years. Other multiples: P/B 1.1, P/S 1.3, EV/EBITDA 10.3.

How solid is the balance sheet of Grand Brilliance Group Holdings Ltd (8372)?

Balance-sheet figures for Grand Brilliance Group Holdings Ltd (as of Sep 27, 2026): return on equity 7.1%. They feed the Quality Score of 60/100, which measures business quality independently of the share price.

How far is 8372 from its 52-week high?

Grand Brilliance Group Holdings Ltd trades at HK$0.1630, at its 52-week high of HK$0.1630 and 70% above the low of HK$0.0960 (as of Sep 30, 2026). Distance from the high says nothing about value: that is what the fair value of HK$0.1700 is for.

Which stocks are comparable to Grand Brilliance Group Holdings Ltd?

From the same area (Healthcare) we also value McKesson Corporation, Cencora, Inc, Cardinal Health, Inc, Henry Schein, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is Grand Brilliance Group Holdings Ltd stock attractive at the current price?

The data as of Sep 27, 2026: price HK$0.1630, calculated fair value HK$0.1700 (+4%), Quality Score 60/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of 8372 calculated?

We run Grand Brilliance Group Holdings Ltd through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$0.1700, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 14.7 % above its aggregate fair value. Grand Brilliance Group Holdings Ltd currently trades 4 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of Grand Brilliance Group Holdings Ltd (8372)?

The closing price on Sep 30, 2026 was HK$0.1630. Our model-based fair value is HK$0.1700, about +4% upside (fairly valued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with Grand Brilliance Group Holdings Ltd right now?

The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (HK$0.1200 to HK$0.2400) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Where does the earnings growth of Grand Brilliance Group Holdings Ltd (8372) come from?

Earnings per share at Grand Brilliance Group Holdings Ltd grew −4.2 % a year from 2016 to 2026. Broken into its drivers: revenue per share +6.9 %, EBIT margin −14.5 %, tax rate +1.1 %, residual (interest, one-offs) +3.5 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Grand Brilliance Group Holdings Ltd

How large is the market capitalisation of Grand Brilliance Group Holdings Ltd (8372)?

The market capitalisation of Grand Brilliance Group Holdings Ltd is HK$130M (≈ $16.6M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of Grand Brilliance Group Holdings Ltd (8372)?

The price-to-sales ratio of Grand Brilliance Group Holdings Ltd is 1.17 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What are the earnings per share of Grand Brilliance Group Holdings Ltd (8372)?

Earnings per share at Grand Brilliance Group Holdings Ltd are HK$0.0200 (price ÷ EPS = P/E 14.0). Earnings per share over the last twelve months: total profit spread across every single share.

What is the dividend yield of Grand Brilliance Group Holdings Ltd (8372)?

The dividend yield of Grand Brilliance Group Holdings Ltd is 1.8% (payout 15.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.

What is the net margin of Grand Brilliance Group Holdings Ltd (8372)?

The net margin of Grand Brilliance Group Holdings Ltd is 8.4% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of Grand Brilliance Group Holdings Ltd (8372)?

The return on equity (ROE) of Grand Brilliance Group Holdings Ltd is 7.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of Grand Brilliance Group Holdings Ltd (8372)?

On an EBIT basis the return on assets of Grand Brilliance Group Holdings Ltd is 5.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of Grand Brilliance Group Holdings Ltd (8372)?

The operating margin of Grand Brilliance Group Holdings Ltd is 7.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at Grand Brilliance Group Holdings Ltd (8372)?

Revenue at Grand Brilliance Group Holdings Ltd is growing −8.6% versus a year earlier (3y avg +9.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How fast are earnings growing at Grand Brilliance Group Holdings Ltd (8372)?

Earnings per share at Grand Brilliance Group Holdings Ltd are growing −27.5% versus a year earlier. How much earnings per share grew versus a year earlier.

How much net cash does Grand Brilliance Group Holdings Ltd (8372) hold?

Grand Brilliance Group Holdings Ltd holds more cash than debt, HK$51.1M net (fiscal year 2026). The company holds more cash than debt, a safety cushion.

Free · no account needed

Watch Grand Brilliance Group Holdings Ltd in the live analysis

One click puts Grand Brilliance Group Holdings Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.